[Ip-health] Reuters: Canada enacts drug price crackdown, in blow to pharmaceutical industry

Thiru Balasubramaniam thiru at keionline.org
Mon Aug 12 00:48:38 PDT 2019


https://www.reuters.com/article/us-canada-pharmaceuticals/canada-enacts-drug-price-crackdown-in-blow-to-pharmaceutical-industry-idUSKCN1UZ0XH

HEALTH NEWS

AUGUST 9, 2019 / 11:35 AM /

Canada enacts drug price crackdown, in blow to pharmaceutical industry

Allison Martell


TORONTO (Reuters) - The Canadian government announced final regulations on
Friday that should cut billions of dollars from patented drug prices that
are among the highest in the world, overcoming heavy opposition from
pharmaceutical companies who may eventually challenge the new rules in
court.

A pharmacist counts prescription drugs at the at the CentreTown Pharmacy in
Ottawa, Ontario, Canada, June 12, 2019. REUTERS/Chris Wattie

The biggest reform to Canada’s drug price regime since 1987 would save
Canadians C$13.2 billion ($10 billion) over a decade. The rules will save
money for patients, employers and insurers including the government at the
expense of drug company profits. They also could eventually cut the
earnings of drugmakers in the United States, the world’s largest
pharmaceutical market.

The Canadian Life and Health Insurance Association called the regulations
“a crucial step to lower prescription drug costs for all Canadians.” The
province of British Columbia also applauded the move, saying in a release:
“People in B.C. and across Canada are now better protected against
excessive drug prices set by manufacturers.”

The new rules were largely in line with a December 2017 draft. They came
after months of delay prompted speculation the government would back down
in the face of industry lobbying or simply run out of time before Canada’s
October election.

“We are taking the biggest step in a generation to lower the price of drugs
in Canada by moving forward with these regulations,” Minister of Health
Ginette Petitpas Taylor said in an interview.

Petitpas Taylor said the new rules would lay the foundation for a new
national drug program. Prime Minister Justin Trudeau’s government is
expected to announce a program to cover the cost of prescription drugs for
some or all Canadians, but the program’s scope is not yet clear.

Canada will change the list of countries the federal drug price regulator,
the Patented Medicine Prices Review Board (PMPRB), compares domestic prices
to, dropping the United States and Switzerland where prices are highest. It
will also let the agency consider cost-effectiveness of new medicines.

It will require drugmakers to disclose some confidential discounts to the
PMPRB, which sets maximum prices.


Initially expected to take effect in January, the regulations were delayed
so the government could review feedback. They will now go into force on
July 1, 2020.

The new features of the regulations, which take into account
cost-effectiveness of medicines and their impact on government budgets,
apply only to drugs approved by Health Canada after the rules are
officially published later this month. Changes in the list of comparison
countries could affect prices for some drugs already on the market.

POTENTIAL FOR COURT CHALLENGE

Canada’s approach to drug pricing is unusual. Rather than bargaining prices
down, the PMPRB declares that some prices are an illegal abuse of patent
rights.

Drugmakers base their list prices on the agency’s published guidelines.
When there is disagreement, PMPRB staff can challenge drugmakers at an
internal tribunal. Most cases are settled, but appeals go to federal court
and beyond.

In the past, drug companies have gone as far as the Supreme Court of Canada
to challenge PMPRB guidelines. With new regulations come new guidelines,
and the potential for fresh court challenges.

“We anticipate a considerable uptick in litigation, at least initially, as
the industry patentees test the boundaries of the new regime,” said Douglas
Clark, executive director of the PMPRB, on a call with reporters. “That’s
to be expected any time you substantially change rules.”

University of British Columbia professor Steve Morgan, who studies access
to drugs and has advocated for a new national drug program, called the
rules “a bold step forward”.

“Now the tricky part: implementation, with all the specifics concerning how
rules will apply; and, no doubt, legal challenges from industry,” he wrote
in a tweet.

Canada's Health Minister Ginette Petitpas Taylor listens to a question
during a news conference on Parliament Hill in Ottawa, Ontario, Canada
November 21, 2017. REUTERS/Chris Wattie/File Photo

REFORMS COULD AFFECT U.S. MARKET

Global drugmakers, including Johnson & Johnson (JNJ.N), Merck & Co (MRK.N)
and Amgen Inc (AMGN.O), argued against the draft plan.

While the government’s focus is on reducing domestic patented drug prices
that are among the highest in the world, the new policy could eventually
have consequences south of the border.

The Trump administration in July said it would allow U.S. states and other
groups to start pilot programs related to importing drugs from Canada. It
has also said it may start determining what the U.S. government healthcare
program Medicare pays for certain medicines based on prices in some other
countries, including Canada.

Reuters reported in February that pharmaceutical lobby groups had tried to
head off the Canadian reforms with an offer to give up C$8.6 billion in
revenue over 10 years, freeze prices or reduce the cost of treating rare
diseases.

Drugmakers argue the reforms could limit Canadians’ access to new medicines.

“The industry does take a lot of risk on in creating these products. It
does cost money,” said Pamela Fralick, president of industry group
Innovative Medicines Canada. “Our fear is that globally, decisions will be
made that products will not be launched in Canada.”

The government said many countries with lower prices have more
pharmaceutical industry investment and access to drugs that meets or
exceeds Canada’s.

Reporting by Allison Martell; editing by Denny Thomas, Nate Raymond and
David Gregorio





-- 
Thiru Balasubramaniam
Geneva Representative
Knowledge Ecology International
41 22 791 6727
thiru at keionline.org


More information about the Ip-health mailing list